Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 1 country.
Szilvia VeszelkaInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, H-6726 Szeged, Hungary.ORCID 0000-0001-8864-1184
Mária MészárosInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, H-6726 Szeged, Hungary.ORCID 0000-0002-4847-9618
Gergő PorkolábInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, H-6726 Szeged, Hungary.ORCID 0000-0002-2495-0479
Ágnes RusznyákDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID 0000-0002-8837-7499
Katalin Szászné Réti-NagyDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID 0000-0001-7830-8337
Mária A DeliInstitute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, H-6726 Szeged, Hungary.ORCID 0000-0001-6084-6524
Miklós VecsernyésDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID 0000-0001-5719-975X
Ildikó BácskayDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID 0000-0001-8663-2890
Judit VáradiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID 0000-0003-1885-164X
Ferenc FenyvesiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei St. 98, H-4032 Debrecen, Hungary.ORCID 0000-0003-2890-0783
University of Debrecen · HUHUN-REN Szegedi Biológiai Kutatóközpont · HUUniversity of Szeged · HU
Funding
Hungarian Academy of Sciences BO/00290/16Hungarian Academy of Sciences BO/00793/18/8Hungarian Academy of Sciences Premium Postdoctoral Research Program of the Hungarian Academy of Sciences (Premium-2019-469)Hungarian Ministry of Innovation and Technology FEIF/433-4/2020-ITM_SZERZNational Research, Development and Innovation Fund of Hungary Project no. TKP2021-EGA-18National Research, Development and Innovation Office FK_17 (FK124634)National Research, Development and Innovation Office GINOP-2.2.1-15-2016-00007National Research, Development and Innovation Office GINOP-2.3.2-15-2016-00060National Research, Development and Innovation Office GINOP-2.3.4-15-2020-00008National Research, Development and Innovation Office NNE-29617 (M-ERA.NET2 nanoPD)National Research, Development and Innovation Office PD138930
6 · The paper itself
Abstract
The application of 2-hydroxypropyl-beta-cyclodextrin (HPBCD) in the treatment of the rare cholesterol and lipid storage disorder Niemann-Pick disease type C opened new perspectives in the development of an efficient therapy. Even if the systemic administration of HPBCD was found to be effective, its low permeability across the blood-brain barrier (BBB) limited the positive neurological effects. Nevertheless, the cellular interactions of HPBCD with brain capillary endothelial cells have not been investigated in detail. In this study, the cytotoxicity, permeability, and cellular internalization of HPBCD on primary rat and immortalized human (hCMEC/D3) brain capillary endothelial cells were investigated. HPBCD shows no cytotoxicity on endothelial cells up to 100 µM, measured by impedance kinetics. Using a fluorescent derivative of HPBCD (FITC-HPBCD) the permeability measurements reveal that on an in vitro triple co-culture BBB model, FITC-HPBCD has low permeability, 0.50 × 10
Indexed as
BrainEndothelial Cells2-Hydroxypropyl-beta-cyclodextrinAnimalsCells, CulturedFluorescein-5-isothiocyanateHumansRats2-Hydroxypropyl-beta-cyclodextrinFluorescein-5-isothiocyanate2-hydroxypropyl-beta-cyclodextrinblood–brain barrierendocytosisNiemann–Pick diseasetype C
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effects of Hydroxypropyl-Beta-Cyclodextrin on Cultured Brain Endothelial Cells. · full record | OpenQuestion